Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Severe renal failure following high-dose ifosfamide and mesna.

Literature DB >> 2495864

Severe renal failure following high-dose ifosfamide and mesna.

P H Willemse¹, P E de Jong, J D Elema, N H Mulder.

Abstract

A 62-year-old woman developed subacute renal failure after the repeated administration of ifosfamide (IFX), despite its combination with continuous sodium 2-mercaptoethane sulfonate (mesna) infusion. Biopsy findings, the possible underlying mechanism, and the existing literature are discussed.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2495864 DOI： 10.1007/bf00292414

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

10 in total

Review 1. Mesna--a short review.

Authors: I C Shaw; M I Graham
Journal: Cancer Treat Rev Date: 1987-06 Impact factor: 12.111

2. Unexpected toxicity in patients treated with iphosphamide.

Authors: J J Van Dyk; H C Falkson; A M Van der Merwe; G Falkson
Journal: Cancer Res Date: 1972-05 Impact factor: 12.701

3. High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.

Authors: H O Klein; P D Wickramanayake; C Coerper; E Christian; J Pohl; N Brock
Journal: Cancer Treat Rev Date: 1983-09 Impact factor: 12.111

4. Ifosfamide--current aspects and perspectives.

Authors: P Hilgard; K Herdrich; W Brade
Journal: Cancer Treat Rev Date: 1983-09 Impact factor: 12.111

5. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.

Authors: G Sangster; S B Kaye; K C Calman; J F Dalton
Journal: Eur J Cancer Clin Oncol Date: 1984-03

6. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.

Authors: R C Stuart-Harris; P G Harper; C A Parsons; S B Kaye; C A Mooney; N F Gowing; E Wiltshaw
Journal: Cancer Chemother Pharmacol Date: 1983 Impact factor: 3.333

7. Clinical overview of mesna.

Authors: H Burkert
Journal: Cancer Treat Rev Date: 1983-09 Impact factor: 12.111

8. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

Authors: M P Goren; R K Wright; C B Pratt; M E Horowitz; R K Dodge; M J Viar; E H Kovnar
Journal: Cancer Res Date: 1987-03-01 Impact factor: 12.701

9. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

Authors: L H Einhorn
Journal: Cancer Chemother Pharmacol Date: 1986 Impact factor: 3.333

10. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).

Authors: N Brock; J Pohl; J Stekar; W Scheef
Journal: Eur J Cancer Clin Oncol Date: 1982-12

10 in total

1. Improvement in karyomegalic interstitial nephritis three years after ifosfamide and cisplatin therapy by corticosteroid.

Authors: Tomokazu Matsuura; Shu Wakino; Ayumi Yoshifuji; Toshifumi Nakamura; Hirobumi Tokuyama; Akinori Hashiguchi; Konosuke Konishi; Takeshi Iwasa; Masaaki Shoji; Ako Hosono; Ken Ohashi; Hirokazu Chuman; Hiroshi Itoh
Journal: CEN Case Rep Date: 2014-06-04

Severe renal failure following high-dose ifosfamide and mesna.

Review 1. Mesna--a short review.

2. Unexpected toxicity in patients treated with iphosphamide.

3. High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.

4. Ifosfamide--current aspects and perspectives.

5. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.

6. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.

7. Clinical overview of mesna.

8. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

9. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

10. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).

1. Improvement in karyomegalic interstitial nephritis three years after ifosfamide and cisplatin therapy by corticosteroid.

Review 2. Renal toxicity and chemotherapy in children with cancer.

3. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.

4. How curable is relapsed Wilms' tumour? The United Kingdom Children's Cancer Study Group.

Review 5. Dosing and side-effects of ifosfamide plus mesna.

6. Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome--a report of two cases.

7. Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy.

Review 8. Anticancer drug-induced kidney disorders.

Review 9. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.

Review 10. Nephrotoxicity as a cause of acute kidney injury in children.